Sandoz介绍FDA批准的Denosumab生物类似物WYOST和Jubbonti,帮助数百万人患骨质疏松症和癌症。 Sandoz introduces WYOST® and Jubbonti®, FDA-approved biosimilars for denosumab, aiding millions with osteoporosis and cancer.

桑多兹已推出WYOST和Jubbonti, 这是美国第一个,也是唯一的由林业发展局批准的可互换生物异物, 供1 000多万骨质疏松症和与癌症有关的骨骼问题患者使用。 Sandoz has launched WYOST® and Jubbonti®, the first and only FDA-approved interchangeable biosimilars for denosumab in the US, offering affordable options for over 10 million patients with osteoporosis and cancer-related skeletal issues. 生物相似物质处理参考药物XGEVA和Prolia的所有迹象。 The biosimilars treat all indications of the reference medicines XGEVA® and Prolia®. Sandoz为患者提供支助资源,包括财政援助。 Sandoz provides support resources for patients, including financial assistance.